Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:FBIO NASDAQ:GHRS NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.01-0.7%$7.27$3.54▼$8.90$184.43M0.8215,278 shs114,674 shsFBIOFortress Biotech$3.71+30.6%$2.10$1.33▼$3.72$110.39M1.61982,875 shs6.38 million shsGHRSGH Research$14.09+0.3%$14.18$6.00▼$20.50$733.08M0.97197,307 shs245,365 shsTBPHTheravance Biopharma$13.95-0.7%$12.12$7.88▼$14.55$702.54M0.04574,998 shs659,988 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical0.00%-2.77%-3.97%-5.14%+46.96%FBIOFortress Biotech0.00%+43.80%+100.54%+85.50%+98.40%GHRSGH Research0.00%+4.37%+16.45%+12.72%+66.35%TBPHTheravance Biopharma0.00%+0.50%+24.44%+24.00%+73.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.01-0.7%$7.27$3.54▼$8.90$184.43M0.8215,278 shs114,674 shsFBIOFortress Biotech$3.71+30.6%$2.10$1.33▼$3.72$110.39M1.61982,875 shs6.38 million shsGHRSGH Research$14.09+0.3%$14.18$6.00▼$20.50$733.08M0.97197,307 shs245,365 shsTBPHTheravance Biopharma$13.95-0.7%$12.12$7.88▼$14.55$702.54M0.04574,998 shs659,988 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical0.00%-2.77%-3.97%-5.14%+46.96%FBIOFortress Biotech0.00%+43.80%+100.54%+85.50%+98.40%GHRSGH Research0.00%+4.37%+16.45%+12.72%+66.35%TBPHTheravance Biopharma0.00%+0.50%+24.44%+24.00%+73.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 2.50Moderate Buy$12.1773.56% UpsideFBIOFortress Biotech 3.00Buy$16.50344.74% UpsideGHRSGH Research 2.88Moderate Buy$32.00127.11% UpsideTBPHTheravance Biopharma 3.50Strong Buy$21.3352.93% UpsideCurrent Analyst Ratings BreakdownLatest DERM, FBIO, GHRS, and TBPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025DERMJourney MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.008/21/2025FBIOFortress BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $17.008/15/2025DERMJourney MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/13/2025DERMJourney MedicalLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/13/2025GHRSGH ResearchZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/27/2025TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $25.006/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$39.006/17/2025TBPHTheravance BiopharmaJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$24.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$56.13M3.29N/AN/A$0.91 per share7.70FBIOFortress Biotech$57.67M1.91N/AN/A($0.06) per share-61.83GHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/ATBPHTheravance Biopharma$64.38M10.91N/AN/A$3.57 per share3.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$14.67M-$0.38N/AN/AN/A-15.49%-48.69%-11.26%11/11/2025 (Estimated)FBIOFortress Biotech-$46M-$1.05N/AN/AN/A-24.84%-301.81%-27.48%11/13/2025 (Estimated)GHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)TBPHTheravance Biopharma-$56.42M$0.2458.1339.86N/A16.88%6.93%3.52%11/11/2025 (Estimated)Latest DERM, FBIO, GHRS, and TBPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBIOFortress Biotech-$0.31-$0.46-$0.15$0.45$14.53 million$16.41 million8/12/2025Q2 2025DERMJourney Medical-$0.07-$0.16-$0.09-$0.16$14.93 million$15.01 million8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical1.111.270.95FBIOFortress Biotech1.341.921.70GHRSGH ResearchN/A29.4929.49TBPHTheravance BiopharmaN/A6.706.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%FBIOFortress Biotech96.51%GHRSGH Research56.90%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%FBIOFortress Biotech27.90%GHRSGH ResearchN/ATBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9026.31 million22.36 millionN/AFBIOFortress Biotech17029.75 million21.45 millionOptionableGHRSGH Research1052.03 millionN/AOptionableTBPHTheravance Biopharma11050.36 million46.89 millionOptionableDERM, FBIO, GHRS, and TBPH HeadlinesRecent News About These CompaniesQ3 Earnings Estimate for TBPH Issued By Zacks ResearchSeptember 7 at 6:50 AM | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Bought by PDT Partners LLCSeptember 6 at 6:11 AM | marketbeat.comResearch Analysts Set Expectations for TBPH Q3 EarningsSeptember 6 at 2:05 AM | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Hits New 12-Month High - Should You Buy?September 4 at 12:31 PM | marketbeat.comTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comWellington Management Group LLP Sells 43,062 Shares of Theravance Biopharma, Inc. $TBPHSeptember 2, 2025 | marketbeat.comRussell Investments Group Ltd. Has $429,000 Stake in Theravance Biopharma, Inc. $TBPHSeptember 2, 2025 | marketbeat.comVanguard Group Inc. Grows Stake in Theravance Biopharma, Inc. $TBPHSeptember 1, 2025 | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Sold by Deutsche Bank AGSeptember 1, 2025 | marketbeat.comNuveen LLC Acquires Shares of 374,952 Theravance Biopharma, Inc. $TBPHAugust 30, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above 50 Day Moving Average - Here's WhyAugust 28, 2025 | marketbeat.comTheravance Biopharma, Inc.: Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic ...August 25, 2025 | finanznachrichten.deTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple ...August 25, 2025 | finance.yahoo.comTheravance Biopharma completes enrollment in CYPRESS studyAugust 25, 2025 | msn.comTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System AtrophyAugust 25, 2025 | prnewswire.comTheravance Biopharma Settles Patent Dispute with CiplaAugust 20, 2025 | msn.comTheravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's What HappenedAugust 20, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street ZenAugust 17, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Price Up 3.4% - Here's WhyAugust 16, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High on Earnings BeatAugust 14, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings ResultsAugust 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDERM, FBIO, GHRS, and TBPH Company DescriptionsJourney Medical NASDAQ:DERM$7.01 -0.05 (-0.71%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.70 -0.31 (-4.41%) As of 09/5/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Fortress Biotech NASDAQ:FBIO$3.71 +0.87 (+30.63%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.94 +0.23 (+6.20%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.GH Research NASDAQ:GHRS$14.09 +0.04 (+0.28%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$13.71 -0.38 (-2.69%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Theravance Biopharma NASDAQ:TBPH$13.95 -0.10 (-0.71%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$14.30 +0.36 (+2.54%) As of 09/5/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
